Alec Stranahan

Eli Lilly & Co. (NYSE:LLY) shares have nosedived 12.5% month-to-date through Nov. 19, putting the stock on track for its worst monthly performance since February 2009, when it tumbled 20.2%. The pharmaceutical giant, which ranks 11th by market capitalization in the S&P 500 and holds the...

A Bank of America analyst remains bearish on Novavax, Inc (NASDAQ: NVAX) after a regulatory panel approved Novavax’s Emergency Use Authorization request for Nuvaxovid, its COVID vaccine. Here's what investors need to know.  The Novavax Analyst: Bank of America analyst Alec...

The S&P 500 is one of the most popular U.S. stock indices and is often what investors and experts are referring to when they mention the "stock market." However, there's more to the market than large-cap stocks. The lesser-known S&P 600 index is another index established by...

Although Novavax, Inc’s (NASDAQ: NVAX) shares have tanked 59% year to date, there is still room for a further decline, according to BofA Securities. The Novavax Analyst: Alec Stranahan initiated coverage of Novavax with an Underperform rating and a price target of $35. The Novavax Thesis:...

Casinos are just starting to open back up following COVID-19 shutdowns, but it may still be a while before some gamblers are willing to venture back to Vegas or even their local casino. Sports gamblers are still waiting for the return of Major League Baseball and other pro and college sports...

Gilead Sciences, Inc. (NASDAQ: GILD) surged more than 16% after hours Thursday when STAT News reported promising preliminary results for a prospective COVID-19 therapy. In a trial conducted by the University of Chicago Medicine, remdesivir has been associated with rapid recovery and near-term...